On the evening of June 14, Tianmao Group announced that the original insurance premium income of its controlled subsidiary, China Best Life Insurance Co., Ltd. from January 1, 2024 to May 31, 2024, was approximately RMB 20.609 billion.
天茂集团：控股子公司国华人寿前5月原保险保费收入约为206.09亿元
Hubei Biocause Pharmaceutical: The original insurance premium income of China Best Life Insurance, a subsidiary controlled by Tianmao Group, was approximately RMB 20.609 billion in the first five months.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.